Microglia-mediated antigen presentation creates a peripheral sink for tau antibodies

Mechanistic rationale: Fcγ receptor-mediated phagocytosis of antibody-opsonized tau targets tau to microglial lysosomes. While this may reduce extracellular tau, it simultaneously triggers microglial activation and inflammatory cytokine release. I hypothesize that this creates a feedback loop that paradoxically accelerates tau release from stressed microglia, explaining the modest efficacy of passive immunotherapy approaches. ## Predicted Outcomes if Hypothesis True 1. Glymphatic enhancers (e.g., α2-adrenergic antagonists, PDE5 inhibitors, sleep intervention) will show greater efficacy for tau pathology reduction than direct immunotherapies 2. Combination approaches targeting both exosome release (synaptobrevin inhibition) and endosomal escape (V-ATPase inhibitors) will show synergistic effects 3. Exosome-derived tau biomarkers will correlate more strongly with disease progression than total CSF tau 4.

Mechanistic rationale: Fcγ receptor-mediated phagocytosis of antibody-opsonized tau targets tau to microglial lysosomes. While this may reduce extracellular tau, it simultaneously triggers microglial activation and inflammatory cytokine release. I hypothesize that this creates a feedback loop that paradoxically accelerates tau release from stressed microglia, explaining the modest efficacy of passive immunotherapy approaches. ## Predicted Outcomes if Hypothesis True 1. Glymphatic enhancers (e.g., α2-adrenergic antagonists, PDE5 inhibitors, sleep intervention) will show greater efficacy for tau pathology reduction than direct immunotherapies 2. Combination approaches targeting both exosome release (synaptobrevin inhibition) and endosomal escape (V-ATPase inhibitors) will show synergistic effects 3. Exosome-derived tau biomarkers will correlate more strongly with disease progression than total CSF tau 4. Anti-exosome antibodies (targeting exosome surface proteins with bound tau) will show superior efficacy to pan-tau antibodies ## Confidence Assessment Overall confidence: 0.72 This reflects strong evidence for the transcellular propagation mechanism, moderate evidence for exosomal involvement, and theoretical but testable predictions for glymphatic targeting. The main weakness is that most mechanistic predictions require validation in human systems—rodent models show clear tau propagation but with important species differences in tau sequence and aggregation propensity. Key caveats: (1) Human clinical validation is pending; (2) the relative contribution of free vs. vesicle-associated tau in human disease remains uncertain; (3) therapeutic modulation of glymphatic function has achieved mixed results in clinical studies; (4) the inflammatory consequences of these interventions require careful monitoring. --- This positions my theoretical framework for subsequent debate rounds, emphasizing the gap between the dominant extracellular targeting strategy and the likely more impactful intervention points at release mechanisms, glymphatic clearance, and endosomal processing.

Debate provenance: derived from debate `sess_SDA-2026-04-04-gap-tau-prop-20260402003221` on question: Tau propagation mechanisms and therapeutic interception points. Consensus signal: domain_expert, skeptic, theorist discussed the mechanism terms CSF, Microglia-mediated, PDE5, activation, aggregation, antibodies, antigen, clearance. Novelty signal: skeptic-discussed-with-qualified-concession.